[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344304-105":59,"doc-detail-344304-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prrt-in-high-grade-digestive-neuroendocrine-neoplasms-net-g3-and-nec","PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)","","Peptide receptor radionuclide therapy (PRRT) has been primarily studied in low and intermediate-grade digestive neuroendocrine tumors (NET G1–G2). Evidence for comparable benefit in high-grade digestive neuroendocrine neoplasms (NEN) has been limited. This review assesses PRRT use in high-grade digestive NEN, covering well-differentiated NET G3 and poorly differentiated neuroendocrine carcinomas (NEC). One phase III trial and seven retrospective studies (more than 10 patients) are reviewed, showing PRRT benefit in NET G3, while NEC data remain scarce and selection criteria are stringent.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prrt-in-high-grade-digestive-neuroendocrine-neoplasms-net-g3-and-nec/344304/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prrt-in-high-grade-digestive-neuroendocrine-neoplasms-net-g3-and-nec/344304.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"PRRT has been studied mainly in which digestive neuroendocrine tumors before this review?","Question",{"text":113,"@type":114},"PRRT has mainly been studied in low- and intermediate-grade digestive neuroendocrine tumors (NET G1–G2).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What evidence supports PRRT for high-grade digestive NET G3?",{"text":118,"@type":114},"A phase III trial (NETTER-2) shows major progression-free survival superiority of PRRT over somatostatin analog therapy for the first-line NET G3 subgroup, and retrospective single-arm studies suggest benefit in NET G3.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is PRRT more difficult to generalize for NEC than for NET G3?",{"text":122,"@type":114},"Data for NEC are scarce, and distinguishing NEC from NET G3 can be challenging, especially when Ki-67 is below 55%, so treatment decisions rely on careful selection criteria.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344304,1790500016,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","DOI: 10.1111/jne.13443  \nINV I T E D R EV IEW  \nPRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)  \nHalfdan Sorbye 1,2  | Grace Kong 3,4 | Simona Grozinsky-Glasberg 5  | Jonathan Strosberg 6   \n1Department of Oncology, Haukeland University Hospital, Bergen, Norway 2Department of Clinical Sciences, University of Bergen, Bergen, Norway  \n3Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia 4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia  \n5Neuroendocrine Tumor Unit, ENETS Center of Excellence, Division of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 6Moffitt Cancer Center, Tampa, Florida, USA  \nCorrespondence  \nHalfdan Sorbye, Department of Oncology, Haukeland University Hospital, Bergen, Norway.  \nEmail: [halfdan.sorbye@helse-bergen.no](halfdan.sorbye@helse-bergen.no)  \nAbstract  \nPeptide receptor radionuclide therapy (PRRT) has been primarily studied in low and intermediate-grade digestive neuroendocrine tumors (NET G1-G2) . The documentation of a similar benefit for high-grade digestive neuroendocrine neoplasms (NEN) has been limited. This review evaluates the use of PRRT for high-grade digestive NEN (well-differentiated NET G3 and poorly differentiated neuroendocrine carcinomas [NEC]). We identified one phase III trial and seven retrospective studies reporting specifically on PRRT outcome of >10 digestive high-grade NEN patients. The retrospective single-arm studies indicate a benefit for PRRT in NET G3 . The randomized phase III NETTER-2 trial demonstrates major PFS superiority of PRRT versus somatostatin analog therapy as the first-line treatment for the NET G3 subgroup. PRRT can now be considered a potential first-line treatment for somatostatin receptor-positive NET G3 patients, but whether it should be the first-line standard of care for all NET G3 patients is still not clarified. For NEC, scarce data are available, and pathologic distinction between NEC and NET G3 can be difficult when Ki-67 is below 55% . PRRT could be considered as a treatment for refractory NEC in very selected cases when there is a high uptake on somatostatin receptor imaging, Ki-67 is below 55%, and there is no rapid tumor progression.  \nKEYWOR DS  \ndigestive, high-grade neuroendocrine neoplasms, neuroendocrine carcinoma, neuroendocrine tumors G3, peptide receptor radionuclide therapy  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.  \nJ Neuroendocrinol. 2025;37:e13443 .  \n[https://doi.org/10.1111/jne.13443](https://doi.org/10.1111/jne.13443)  \n[wileyonlinelibrary.com/journal/jne](wileyonlinelibrary.com/journal/jne)  \n1 of 8  \n1 | BACKGROUND  \n1.1 | High-grade digestive neuroendocrine neoplasms: Neuroendocrine tumor G3 and neuroendocrine carcinoma  \nThe 2019 WHO classification of tumors of the digestive system separates high-grade (HG) digestive NEN with a Ki-67 index above 20% into two distinct entities: well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinoma (NEC) .1 Digestive NET G3 and NEC differ in clinical and molecular characteristics, and response to treatment and prognosis.2–6 Distinguishing NET G3 from NEC is occasionally challenging, even among NET specialists.7  \n1.2 | Digestive NET G3  \nDigestive NET G3 is seen in 15%–20% of HG digestive NEN cases, and the primary tumor is most frequently found in the pancreas.4–6 Median Ki-67 is typically around 30% . Few cases have a Ki-67 above 55% and then the clinical course resembles NEC. Most NET G3 present with metastati","cbCaihAfUIfyttmg","https://ap.wps.com/l/cbCaihAfUIfyttmg","pdf",1400234,"English","# Background\n## High-grade digestive neuroendocrine neoplasms: Neuroendocrine tumor G3 and neuroendocrine carcinoma\n## Digestive NET G3\n## Digestive NEC","[{\"question\":\"PRRT has been studied mainly in which digestive neuroendocrine tumors before this review?\",\"answer\":\"PRRT has mainly been studied in low- and intermediate-grade digestive neuroendocrine tumors (NET G1–G2).\"},{\"question\":\"What evidence supports PRRT for high-grade digestive NET G3?\",\"answer\":\"A phase III trial (NETTER-2) shows major progression-free survival superiority of PRRT over somatostatin analog therapy for the first-line NET G3 subgroup, and retrospective single-arm studies suggest benefit in NET G3.\"},{\"question\":\"Why is PRRT more difficult to generalize for NEC than for NET G3?\",\"answer\":\"Data for NEC are scarce, and distinguishing NEC from NET G3 can be challenging, especially when Ki-67 is below 55%, so treatment decisions rely on careful selection criteria.\"}]","PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) | PDF",1790053372,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/091fd6ab6744d7d44822cbf8cb7ccf94.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4c98526a36ef9ea8667900fec8b71f3.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a549616e36c78c80aedab863ea9a4e7.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d611181d1d5f08d663f2cb988c7c35f.webp",980,1287]